An observational study in Parkinson Disease and Dysarthria, Hypokinetic, sponsored by Florida State University. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by Florida State University · Observational
Articulatory deficits are present in most speakers with dysarthria, which negatively impacts their speech intelligibility, yet little is known about the relationship between articulatory movement and speech intelligibility. This study will examine the relationship between articulation measures, both acoustic and kinematic, and their relationship to perceptual measures (i.e., speech intelligibility and articulation ratings) in 30 individuals with dysarthria secondary to Parkinson's disease and 30 neurologically healthy adults of the same age. The findings will have implications for behavioral management.
Dysarthria is a motor speech disorder that affects individuals with various etiologies. Parkinson's disease (PD) alone affects nearly one million individuals in the U.S., with dysarthria developing in approximately 90% of these individuals within the first two years of onset. The dysarthria associated with PD is characterized by reduced movement, which has been supported by findings of reduced lip, tongue, and jaw movement in speakers with PD. However, it remains unclear if hypokinetic dysarthria causes a global reduction across all articulators, or if specific articulators are disproportionally affected by the disease. Further, it is not fully understood what factors contribute to speech intelligibility. Specifically, little is known about the articulatory-kinematic correlates of speech intelligibility. This missing link is vital to understand, as articulation deficits are a universal characteristic of dysarthria, regardless of etiology. The proposed study provides a linked investigation of kinematic, acoustic, and perceptual characteristics in speakers with PD and neurologically healthy speakers.
This research aims to (1) examine the perceptual, acoustic, and articulator-specific movement deficits in speakers with PD and (2) understand the relationship between articulatory movement and measures of speech perception. Specific Aim 1 will examine the group differences between speakers with PD and neurologically healthy speakers using perceptual, acoustic, and articulator-specific kinematic measures. The investigators hypothesize the perceptual, acoustic, and tongue-related kinematic measures will differentiate individuals with PD from neurologically healthy speakers. Specific Aim 2 will model speech intelligibility (Specific Aim 2a) and ratings of articulatory precision (Specific Aim 2b) using selected acoustic and kinematic measurements. The investigators hypothesize that the acoustic measures will be stronger predictors of speech intelligibility than the kinematic measures, as they are both derived from the speech signal. Further, the investigators hypothesize the selected kinematic measures may demonstrate a stronger relationship to articulation ratings than speech intelligibility. This study is a requisite step toward our long-term goal of advancing dysarthria management strategies. The primary outcome will be explanatory models that identify acoustic and articulatory correlates of speech intelligibility and articulatory precision. This study has important implications for developing articulator-specific dysarthria management strategies to supplement universal dysarthria management strategies.
4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
This study's enrollment of 40 is below the median of 96 across 1,085 observational studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Florida State University is the lead sponsor of 249 studies on the registry; 47 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
All participants will be recruited via convenient sampling from Tallahassee, FL, and the local community. For the neurologically healthy control speakers, flyers will be posted at local coffee shops, community samples, and via word of mouth. For the Parkinson's participants, flyers will be posted at hospitals, health clinics, and gyms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort includes individuals who have been diagnosed with Parkinson's disease.
Behavioral: Clear Speech · Behavioral: Less Clear Speech
This group consists of age-matched control participants. They are neurologically healthy and do not have any neurological diagnoses.
Behavioral: Clear Speech · Behavioral: Less Clear Speech
This behavioral modification asks participants to speak more clearly, as if they were "speaking to someone with a hearing loss".
This behavioral modification asks participants to speak less clearly, as if they were "in a room with many people and they were mumbling something to the person next to them that they didn't want other people in the room to hear."
Vowel Space Area
Vowel space area is a measure of the planar area among the four corner vowels /i/, /ae/, /a/, and /u/. It is calculated using the first and second formant resonant frequencies obtained from the acoustic signal, using the software PRAAT.
Time frame: Baseline
F2 Slope
Second formant frequency (F2) slope is measured as the rate of F2 change during the diphthong in "Buy." To calculate this measure, first the investigators will obtain the extent of F2 change (max F2 - min F2) from the diphthong "Buy." Then this F2 change is divided by the duration of the diphthong "Buy."
Time frame: Baseline
Tongue and Jaw Speed
This is measured as the tongue and jaw speed during the diphthong in "Buy". Specifically, this will be calculated as tongue/jaw movement (measured in mm), divided by movement duration (measured in ms). The tongue and jaw movement will be collected using the electromagnetic articulography (EMA) device used in this study.
Time frame: Baseline
Acoustic Distance
This is measured as the Euclidean distance between the second formant frequency (F2) onset and offset of the diphthong in "Buy" in an F1-F2 (first and second formant frequency) space. Measured in Hz.
Time frame: Baseline
Tongue and Jaw Distance
This is measured as the Euclidean distance between the tongue and jaw onset and offset of the diphthong in "Buy" in a two-dimensional space.The tongue and jaw movement will be collected using the electromagnetic articulography (EMA) device used in this study.
Time frame: Baseline
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The analytic data and code will be shared to the open science framework (OSF) upon completion of the project, expected July 2023.
Supporting information: Analytic code
Time frame: Analytic data and code will be made available in July 2023.
Access criteria: Upon publication to the open science framework (OSF) project page, anyone will have access to the analytic data and code.
Data sharing details ↗ · osf.io
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.